1003944-35-1

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
8-Bromo-2,7-dimethoxy-1,5-naphthyridine is utilized as a chemical compound in pharmaceutical research and drug development for its potential applications in treating various medical conditions. The bromine atom and methoxy groups enhance its chemical properties, which may contribute to its effectiveness in addressing specific health issues.
Used in Treatment of Medical Conditions:
In the medical field, 8-Bromo-2,7-dimethoxy-1,5-naphthyridine is employed as a potential therapeutic agent for the treatment of various conditions. Its unique structure and functional groups may offer advantages in targeting specific biological pathways or mechanisms, leading to improved treatment outcomes.
Used as a Chemical Tool for Biological Investigations:
8-Bromo-2,7-dimethoxy-1,5-naphthyridine also serves as a chemical tool in biological research, allowing scientists to further explore its biological effects and mechanisms of action. This understanding can contribute to the development of new drugs or therapies based on the compound's properties and interactions with biological systems.

Upstream product

• 724788-70-9 8-bromo-7-fluoro-2-methoxy-1,5-naphthyridine 
• 124-41-4 sodium methylate 

Downstream Products

• 1173896-46-2 1-(2-(4-((3,4-dichlorobenzyl)amino)piperidin-1-yl)ethyl)-7-methoxy-1,5-naphthyridin-2(1H)-one 
• 959615-59-9 7-methoxy-1,5-naphthyridin-2(1H)-one 

Relevant academic research and scientific papers

Mycobacterium tuberculosis gyrase inhibitors as a new class of antitubercular drugs

One way to speed up the TB drug discovery process is to search for antitubercular activity among compound series that already possess some of the key properties needed in anti-infective drug discovery, such as whole-cell activity and oral absorption. Here, we present MGIs, a new series of Mycobacterium tuberculosis gyrase inhibitors, which stem from the long-term efforts GSK has dedicated to the discovery and development of novel bacterial topoisomerase inhibitors (NBTIs). The compounds identified were found to be devoid of fluoroquinolone (FQ) cross-resistance and seem to operate through a mechanism similar to that of the previously described NBTI GSK antibacterial drug candidate. The remarkable in vitro and in vivo antitubercular profiles showed by the hits has prompted us to further advance the MGI project to full lead optimization.

NAPHTHYRIDIN-2 (1 H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS

Compounds of Formula (I) wherein substituents R1, R2 and R5 are as defined, and Ar represents substituted phenyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, furanyl, imidazolyl and thiophenyl substituted by a hydroxyalkyl substituent and an optional other substituent; compositions containing them, their use in therapy, including their use as antibacterials, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.